Financial Performance - The company's operating revenue has decreased due to market competition and project progress not meeting expectations[4]. - The company's operating revenue for 2024 was ¥754,058,316.42, a decrease of 10.49% compared to ¥842,437,861.81 in 2023[24]. - The net profit attributable to shareholders for 2024 was ¥14,421,866.44, down 82.64% from ¥83,097,173.11 in 2023[24]. - The net profit after deducting non-recurring gains and losses for 2024 was ¥5,008,448.99, a decline of 91.74% from ¥60,627,190.84 in 2023[24]. - The total assets at the end of 2024 were ¥1,946,989,678.97, a decrease of 2.49% from ¥1,996,714,366.68 at the end of 2023[24]. - The net assets attributable to shareholders at the end of 2024 were ¥1,285,002,665.68, down 3.29% from ¥1,328,730,441.04 at the end of 2023[24]. - The basic earnings per share for 2024 were ¥0.1453, an 85.06% decrease from ¥0.9728 in 2023[24]. - The weighted average return on equity for 2024 was 1.10%, down from 9.41% in 2023[24]. - The company reported a significant decline in quarterly performance, with the fourth quarter showing a net profit loss of -¥5,624,438.25[27]. Revenue Breakdown - Revenue from medical gas equipment and systems decreased by 46.50% to 221,936,543.71 CNY, accounting for 29.43% of total revenue[69]. - Revenue from medical clean equipment and systems increased by 32.06% to 493,308,597.63 CNY, representing 65.42% of total revenue[69]. - Operating revenue from maintenance services rose by 16.35% to 13,916,300.05 CNY, making up 1.85% of total revenue[69]. - The Northeast region saw a revenue increase of 102.61%, while the Central region experienced a significant decline of 85.46%[69]. Research and Development - The company plans to continue investing in research and development to enhance product competitiveness and meet market demand[4]. - The R&D team consists of highly qualified professionals across multiple disciplines, ensuring a strong foundation for innovation[51]. - The company has established a comprehensive R&D management mechanism, optimizing resource allocation and enhancing product development capabilities[53]. - Major R&D projects completed include the optimization of medical gas equipment and the development of a new electric surgical table, all aimed at meeting market demands[78][79]. - The company aims to enhance product types and reduce production costs through new product developments, which are expected to drive revenue growth[78][79]. Market Position and Strategy - The company aims to strengthen cost control and shorten the collection period to improve operational capabilities and performance[4]. - The company plans to expand its market presence through partnerships and potential acquisitions to strengthen its competitive position in the medical equipment sector[21]. - The company is actively exploring opportunities in international markets to diversify its revenue streams and reduce dependency on domestic sales[25]. - The company has established strong partnerships with numerous medical institutions, focusing on the sale of medical gas equipment and cleanroom systems, as well as related products[43]. Governance and Compliance - The company has a robust information disclosure system, ensuring timely and accurate reporting to shareholders and regulatory bodies[128]. - The company has maintained a high level of attendance at board meetings, with no directors missing two consecutive meetings[157]. - The company has appointed three independent directors, complying with the requirements set by the China Securities Regulatory Commission[127]. - The company has established a performance evaluation and incentive mechanism for directors, supervisors, and senior management, ensuring transparency and compliance with legal regulations[126]. Cash Flow and Investments - Operating cash inflow for 2024 was CNY 739,860,391.86, a 2.20% increase from CNY 723,934,248.05 in 2023[82]. - Investment cash inflow surged by 831.78% to CNY 384,727,807.37 in 2024 from CNY 41,289,639.28 in 2023[82]. - The total investment during the reporting period was 416 million yuan, reflecting a 100% increase compared to the previous year[92]. - The company has committed to invest a total of 33.5 million in the Smart Medical Equipment Production Base project, with a completion rate of 6% as of July 2023[98]. Employee and Talent Development - The total number of employees at the end of the reporting period is 1,130, with 784 from the parent company and 346 from major subsidiaries[163]. - The company has a strong focus on talent development, providing various training programs to improve employee skills and capabilities[57]. - The company has established a comprehensive annual training plan for 2024, focusing on enhancing employee skills and knowledge through both online and offline training[166]. Risk Management - The company faces risks from intensified market competition, particularly in the medical gas and clean equipment sectors, which may affect its market position[111]. - The company is at risk of bad debts due to increasing accounts receivable from public hospitals, which may be affected by macroeconomic conditions[114]. - To mitigate risks, the company will increase R&D investment and enhance its product pipeline to improve core competitiveness[112]. Environmental and Social Responsibility - The company actively responded to national policies on poverty alleviation and rural revitalization, prioritizing local employment in its projects[181]. - The company has committed to harmonizing economic and social benefits in its operations, contributing to local economic development[181]. - The company strictly adheres to labor laws and regulations, ensuring the protection of employee rights and interests[180].

Revenue and Profitability - Revenue for Q1 2025 was CNY 24,286,732.74, a decrease of 68.09% compared to CNY 76,119,952.75 in the same period last year[5] - Net profit attributable to shareholders was CNY 1,578,952.62, down 85.25% from CNY 10,707,388.40 year-on-year[5] - Basic and diluted earnings per share were CNY 0.0161, down 85.00% from CNY 0.1073 in the same period last year[5] - The net profit for the current period is 1,578,952.62, a significant decrease from 10,707,388.40 in the previous period, representing a decline of approximately 85.2%[20] - The operating profit for the current period is 1,538,872.30, down from 10,618,920.79 in the previous period, indicating a decrease of about 85.5%[20] - The total comprehensive income for the current period is 1,578,952.62, down from 10,707,388.40 in the previous period, reflecting a decrease of about 85.2%[20] Cash Flow and Liquidity - Net cash flow from operating activities was negative CNY 15,090,975.28, a decline of 140.24% compared to CNY 37,498,382.94 in the previous year[5] - Cash flow from operating activities shows a net outflow of -15,090,975.28, compared to a net inflow of 37,498,382.94 in the previous period, reflecting a substantial change in cash flow dynamics[22] - Total cash and cash equivalents at the end of the period stand at 486,663,948.02, down from 694,758,375.54 at the end of the previous period, a decrease of approximately 30%[23] - The company reported cash inflows from investment activities of 81,292,444.44, while cash outflows totaled 195,512,870.38, resulting in a net cash outflow of -114,220,425.94 from investment activities[23] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,957,273,279.76, an increase of 0.53% from CNY 1,946,989,678.97 at the end of the previous year[5] - The total liabilities at the end of the period are CNY 709,642,530.16, an increase of 7.2% from CNY 661,987,013.29 at the beginning of the period[17] - The accounts receivable decreased to CNY 638,636,200.10, down 9.5% from CNY 705,456,938.63 at the beginning of the period[15] - The inventory increased to CNY 254,737,658.66, up 24.7% from CNY 204,203,626.98 at the beginning of the period[15] Operational Performance - The total operating revenue for the current period is CNY 24,286,732.74, a decrease of 68.1% compared to CNY 76,119,952.75 in the previous period[19] - The total operating costs for the current period amount to CNY 33,730,745.31, down 56.5% from CNY 77,757,539.66 in the previous period[19] - The company experienced a significant reduction in cash inflows from sales of goods and services, which totaled 138,755,526.69, compared to 257,093,414.86 in the previous period, a decline of approximately 46.0%[22] - The company reported a decrease in operating cash inflows, totaling 147,940,993.16, down from 269,434,763.64 in the previous period, indicating a decline of about 45.0%[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 8,455[9] - The company has a scheduled release of restricted shares for major shareholders on January 27, 2025, which may impact future stock performance[13] Financing Activities - Short-term borrowings rose by 32.26% year-on-year, primarily due to an increase in working capital loans[10] - The company raised 96,000,000.00 in borrowings during the current period, compared to 75,102,630.93 in the previous period, indicating an increase of approximately 28% in financing activities[23] Research and Development - The company plans to continue focusing on research and development, with R&D expenses amounting to CNY 4,280,463.49 for the current period[19] Inventory Management - Inventory shares increased by 167.17% year-on-year, attributed to the implementation of share buybacks[10] - Prepayments increased by 92.56% year-on-year, mainly due to an increase in procurement prepayments[10] Investment Income - Investment income decreased by 100% year-on-year, as there were no interest earnings from structured deposits in the current period[10]

Core Viewpoint - The company, 港通医疗, is experiencing a decline in stock price and profitability, with a significant drop in net profit despite a modest increase in revenue, indicating potential challenges in the medical device industry [1][2]. Company Overview - 港通医疗 specializes in the research, design, manufacturing, integration, and operation services of medical gas equipment and clean equipment systems [1]. - The company's main products include medical central oxygen systems, medical central suction systems, medical air supply systems, medical gas alarm systems, and medical molecular sieve oxygen systems, among others [1]. - 港通医疗 has obtained 25 medical device registration certificates or filing credentials and was the first in China to pass the National Medical Products Administration's review for medical carbon dioxide excipients [1]. Financial Performance - For the third quarter of 2024, the company reported a revenue of 4.92 billion yuan, representing a year-on-year increase of 13.40% [2]. - The net profit for the same period was 20.0463 million yuan, showing a significant year-on-year decrease of 46.99% [2]. - The company's sales gross margin stood at 20.02% [2]. Market Position - 港通医疗's rolling price-to-earnings (PE) ratio is 27.44, compared to the industry average of 45.94 and the industry median of 29.64, placing it 69th in the industry ranking [1][2]. - The total market capitalization of 港通医疗 is 1.793 billion yuan [2]. - As of the latest report, 62 institutions hold shares in 港通医疗, with a total holding of 1.0387 million shares valued at 0.19 billion yuan [1].

4月14日，港通医疗今日收盘18.12元，上涨1.23%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到27.74倍，总市值18.12亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均45.71倍，行业中值29.99倍，港通医疗排 名第68位。 股东方面，截至2025年3月31日，港通医疗股东户数8455户，较上次减少143户，户均持股市值35.28万 元，户均持股数量2.76万股。 四川港通医疗设备集团股份有限公司主营业务为医用气体装备及系统、医用洁净装备及系统的研发、设 计、制造、集成及运维服务。公司主要产品包括医用中心供氧系统、医用中心吸引系统、医用空气集中 供应系统、医用气体报警系统、医用分子筛制氧系统等Ⅱ类医疗器械及其他成套设备。在医用洁净装备 及系统方面，公司集成净化空调系统、电气系统、智能控制系统及相关设备，主要应用于医院手术部、 ICU、负压隔离病房等区域。公司已取得25项医疗器械注册证或备案凭证。长期以来，公司专注于相关 领域的研发和拓展，2021年3月公司成为国内首家通过国家药监局医用二氧化碳药用辅料关联审评审批 的企业，实现行业突破。 最新一期业绩显示，2024 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、对外投资概述 为满足未来的业务发展需要，四川港通医疗设备集团股份有限公司（以下简 称"公司"）以自有资金认缴出资额 408 万元人民币投资设立港通智联数字科技 （重庆）有限公司（以下简称"港通智联"），持股比例为 51%。 证券代码：301515 证券简称：港通医疗 公告编号：2025-013 四川港通医疗设备集团股份有限公司 关于设立控股子公司暨完成工商登记注册的公告 港通智联成为公司控股子公司，纳入公司合并财务报表范围。根据《深圳证 券交易所创业板股票上市规则》等相关规定，本次对外投资在公司经营层决策权 限范围内，无需提交公司董事会、股东会审议。本次对外投资事项不构成关联交 易，也不构成《上市公司重大资产重组管理办法》规定的重大资产重组。 二、控股子公司基本情况 名称：港通智联数字科技（重庆）有限公司 统一社会信用代码：91500000MAEF366070 类型：有限责任公司 住所：重庆市两江新区大竹林街道杨柳路 3 号 1 幢 26 层 26-6 法定代表人：韦渤 注册资本：捌佰万元整 成立日期：202 ...

4月9日，港通医疗今日收盘17.52元，上涨2.28%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到26.82倍，总市值17.52亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)68港通医疗26.8221.081.3417.52亿行业平均 45.1547.484.67100.63亿行业中值28.6628.362.2442.39亿1硕世生物-1741.61-1741.611.0935.98亿2诺唯 赞-520.51-520.512.2588.50亿3博晖创新-332.64-204.803.6651.06亿4康泰医学-259.9030.492.6650.55亿5华 大基因-197.85216.412.05201.05亿6奥精医疗-106.24-106.241.3519.25亿7睿昂基因-76.19-76.191.1811.02亿 8华大智造-54.64-54.644.10327.38亿9热景生物-50.04-50.042.7589.68亿10中红医疗-47.61-32.390.7542.39亿 11天智航-41.77-41.774.3651.42亿 来源：金融界 截至2024年三季报 ...

4月1日，港通医疗今日收盘19.35元，上涨3.92%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到29.62倍，总市值19.35亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均46.46倍，行业中值33.07倍，港通医疗排 名第67位。 截至2024年三季报，共有62家机构持仓港通医疗，其中基金62家，合计持股数103.87万股，持股市值 0.19亿元。 四川港通医疗设备集团股份有限公司主营业务为医用气体装备及系统、医用洁净装备及系统的研发、设 计、制造、集成及运维服务。公司主要产品包括医用中心供氧系统、医用中心吸引系统、医用空气集中 供应系统、医用气体报警系统、医用分子筛制氧系统等Ⅱ类医疗器械及其他成套设备。在医用洁净装备 及系统方面，公司集成净化空调系统、电气系统、智能控制系统及相关设备，主要应用于医院手术部、 ICU、负压隔离病房等区域。公司已取得25项医疗器械注册证或备案凭证。长期以来，公司专注于相关 领域的研发和拓展，2021年3月公司成为国内首家通过国家药监局医用二氧化碳药用辅料关联审评审批 的企业，实现行业突破。 最新一期业绩显示，2024年三季报，公司实现营业收 ...

证券代码：301515 证券简称：港通医疗 公告编号：2025-012 四川港通医疗设备集团股份有限公司 关于2024年第二次回购公司股份比例达到2%暨回购进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 四川港通医疗设备集团股份有限公司（以下简称"公司"）于 2024 年 11 月 4 日召开第四届董事会第十七次会议和第四届监事会第十七次会议，审议通过 《关于 2024 年第二次回购公司股份方案的议案》，公司拟使用不低于人民币 5,000 万元（含）且不超过人民币 10,000 万元（含）的自有资金和专项回购贷款 资金以集中竞价交易的方式回购公司已发行的人民币普通股（A 股）股票，回购 价格不超过人民币 28.49 元/股（含），回购的股份将用于实施员工持股计划或股 权激励。本次回购股份的实施期限为自公司董事会审议通过本次回购股份方案之 日起不超过 12 个月。具体回购股份的数量以回购期满或回购完毕时公司实际回 购的股份数量为准。 公司于 2024 年 11 月 8 日召开 2024 年第一次临时股东会，审议通过《关于 公司 2024 年前三季度利 ...

关于子公司变更经营范围暨完成工商变更登记的 公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：301515 证券简称：港通医疗 公告编号：2025-011 四川港通医疗设备集团股份有限公司 四川港通医疗设备集团股份有限公司（以下简称"公司"）的全资子公司四 川美迪法医疗设备有限公司，为满足未来的业务发展需要，对其经营范围进行了 变更，相关工商变更登记手续已于近日办理完毕，并取得了四川省资阳市行政审 批局换发的《营业执照》，主要情况如下： 变更内容 变更前 变更后 经营范围 许可项目：第二类医疗器械生产。 （依法须经批准的项目，经相关 部门批准后方可开展经营活动， 具体经营项目以相关部门批准文 件或许可证件为准）一般项目：第 一类医疗器械销售；第一类医疗 器械生产；第二类医疗器械销售。 （除依法须经批准的项目外，凭 营业执照依法自主开展经营活 动） 许可项目：第二类医疗器械生产。（依 法须经批准的项目，经相关部门批准 后方可开展经营活动，具体经营项目 以相关部门批准文件或许可证件为 准）一般项目：第一类医疗器械销售； 第一类医疗器械生产；第二类医疗 ...

港通医疗收盘上涨1.94%，滚动市盈率29.01倍，总 市值18.95亿元 3月26日，港通医疗今日收盘18.95元，上涨1.94%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到29.01倍，总市值18.95亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均45.14倍，行业中值31.99倍，港通医疗排 名第67位。 截至2024年三季报，共有1家机构持仓港通医疗，其中基金1家，合计持股数1.70万股，持股市值0.00亿 元。 最新一期业绩显示，2024年三季报，公司实现营业收入4.92亿元，同比13.40%；净利润2004.63万元， 同比-46.99%，销售毛利率20.02%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)67港通医疗29.0122.801.4518.95亿行业平均 45.1449.524.84107.93亿行业中值31.9931.002.4848.44亿1硕世生物-1949.53-1949.531.2340.28亿2诺唯 赞-562.38-562.382.4395.62亿3利德曼-363.03174.161.5426.71亿4博晖创新-300.71- ...